Gaboxadol (THIP) – Kodiac biolabs

Our opinion on this compoundNiche research probe

61/100

The canonical extrasynaptic delta-GABA-A probe; therapeutically abandoned but mechanistically irreplaceable for tonic inhibition research

Look, gaboxadol is a weird one to rate because it exists in two completely separate stories simultaneously. The first story is a clinical failure: Lundbeck and Merck took it through Phase 3 in primary insomnia, watched patients experience disorientation and hallucinations, and pulled the plug in 2007. That story is over. The second story is the interesting one, and its the reason gaboxadol belongs in this library at all.

Here’s the thing about the mechanism. Most GABA pharmacology targets synaptic receptors, the alpha1/2/3-beta-gamma2 isoforms that benzodiazepines and z-drugs hit. Those receptors mediate phasic inhibition, fast transient signals. Gaboxadol does something different: it’s a superagonist at extrasynaptic GABA-A receptors bearing the delta subunit, primarily alpha4-beta3-delta and alpha6-beta3-delta, and those receptors mediate tonic inhibition, the continuous low-amplitude background current that sets the excitability baseline of a neuron. Thats a genuinely different biological variable, and most of the GABA pharmacology toolkit doesn’t let you isolate it cleanly.

We think the differentiation here is underappreciated. Muscimol hits both synaptic and extrasynaptic receptors indiscriminately. DS2, a delta-selective PAM, modulates the receptor but doesn’t agonize it directly. If you want to study what delta-subunit tonic GABA-A current actually does in a circuit, gaboxadol is effectively the only clean pharmacological lever. That’s a real niche, and it’s gotten more interesting since the brexanolone and zuranolone data validated the delta-subunit angle for neurosteroid-sensitive states. Labs working on PMDD biology, alcohol use disorder, stress-related changes in inhibitory tone, or sleep architecture at the subunit level are going to want this compound on the shelf.

The evidence picture is decent for a failed drug. Multiple Phase 3 trials ran to completion before the adverse event signal emerged. That means there’s actual human pharmacology data: real EEG effects, real sleep architecture changes, real CNS penetration confirmed by the adverse events themselves. Preclinical literature is solid and multi-lab. The translational signal is real but it points toward a wall therapeutically, which is why the score here isn’t higher overall.

Honestly, if you’re not working on GABA-A subunit biology specifically, this compound probably isn’t your priority. The clinical failure isn’t a reason to ignore it, but it does mean the research community actively using it is a specialist one. For those investigators, it’s close to indispensable. For everyone else, it’s a footnote in GABA pharmacology history with a genuinely interesting mechanism they probably won’t have occasion to use.

Novelty: 48
Mechanism promise: 68
In-category differentiation: 72
Evidence quality: 60
Translational signal: 45
Research bench value: 75

Rationale Gaboxadol failed Phase 3 as a hypnotic due to adverse psychiatric events, but the mechanism is intact and validated; it scores high on differentiation and bench value because no other compound selectively probes extrasynaptic delta-containing GABA-A receptors with the same precision, making it indispensable for labs working on tonic inhibition, neurosteroid sensitivity, or delta-subunit biology specifically.

Selective extrasynaptic GABA-A delta-subunit agonist

A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

Abstract

Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-255Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.